MPR First Report

All articles by MPR First Report

African Americans, Whites, Differ in Decision-making Regarding Preferences for Cancer Pain Treatment

A pilot study designed to understand how preferences for analgesic treatment for cancer pain vary between African Americans and whites found that each group may employ different heuristics in making decisions, despite having similar levels of education and health literacy, according to data presented at the American Pain Society’s 29th Annual Scientific Meeting.

Intranasal Ketorolac Provides Nonopioid Option for Acute Moderate-to-Severe Pain

Intranasal ketorolac provides an efficacious option for management of acute moderate-to-severe pain, results of phase 2/3 placebo-controlled trials have found. These results, which were presented at the American Pain Society’s 29th Annual Scientific Meeting, may be particularly useful for ambulatory patients, when opioid use should be avoided or reduced, Lincoln Bynum, MD, and colleagues of ICON Development Solutions, Redwood City, Calif., reported.

Enteric-Coated Aspirin Plus Immediate-Release Omeprazole—Reduces Incidence of Gastroduodenal Ulcers

The novel therapeutic agent PA65020 (enteric-coated aspirin plus immediate-release omeprazole) significantly reduced gastrointestinal mucosal damage after 28 days of treatment compared with enteric-coated aspirin (EC-ASA) alone. Results of this single-center, phase I, randomized, double-blind study suggest that for at-risk patients requiring analgesic doses of aspirin, PA65020 may be an important option according to a study presented at the 29th Annual Scientific Meeting of the American Pain Society.

EXALGO Provides 24-Hour Management of Moderate-to-Severe Chronic Pain

Patients with moderate-to-severe chronic pain can be successfully converted from prior opioid therapy to EXALGO (hydromorphone HCl) extended-release tablet, an extended-release (ER) oral formulation of hydromorphone HCl, according to a presentation at the American Pain Society 29th Annual Scientific Meeting. Approved by the US Food and Drug Administration on March 1, 2010, EXALGO is the only ER formulation of hydromorphone available in the US.

Children with Limb Trauma Remain Suboptimally Treated for Pain in Emergency Departments

Despite receiving ibuprofen and codeine, children presenting to an emergency department (ED) with limb trauma had moderately high pain scores after 120 minutes. These results suggest that to reach a clinically significant decrease in pain, an NSAID should be combined with an opioid stronger than codeine, researchers reported at the American Pain Society’s 29th Annual Scientific Meeting.

Elderly Patients with Moderate-to-Severe Low Back or Osteoarthritis Pain Tolerate Tapentadol Immediate Release (IR) Better than Oxycodone IR

Lower incidences and rates of discontinuation due to gastrointestinal treatment-emergent adverse events (TEAEs) among elderly patients with moderate-to-severe low back or osteoarthritis pain suggest that tapentadol immediate-release (IR) may be a better treatment option than oxycodone IR, according to a study presented during the 29th Annual Scientific Meeting of the American Pain Society.

Novel and Future Directions in Cancer Pain Management

Presence of pain is often the first sign of cancer; approximately 20% to 75% of patients present with pain at the time of diagnosis. . At the 29th Annual Scientific Meeting of the American Pain Society, Christine Miaskowski, RN, PhD, FAAN, of the University of California at San Francisco, San Francisco, Calif., highlighted the importance of evaluating cancer pain etiologies as well as interindividual variability when managing cancer patients with pain.

For Acute, Painful Musculoskeletal Conditions, Cyclobenzaprine Enables More Rapid Return to Function than Placebo

Patients with acute, painful musculoskeletal conditions can be returned to normal activities rapidly if the spasm-pain-spasm cycle is interrupted promptly. Therefore, time to response following medication administration is a clinically meaningful assessment in this patient population, investigators reported during the American Pain Society’s 29th Annual Scientific Meeting.

Comorbid Migraine Does Not Affect Efficacy of Milnacipran in Management of Fibromyalgia

In patients with fibromyalgia, milnacipran efficacy is not affected by the presence of comorbid migraine headache, examination of pooled data from three randomized, double-blind, placebo-controlled clinical trials of the dual serotonin- and norepinephrine-reuptake inhibitor has found.The study was presented at The American Pain Society’s 29th Annual Scientific Meeting.